soul trial oral semaglutide cardiovascular outcomes results 2024 SOUL (Semaglutide cardiOvascular oUtcomes triaL) in individuals with Oral semaglutide found to lower

Retatrutide is an investigational triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, enhancing insulin secretion, suppressing appetite, increasing energy expenditure, and promoting hepatic fat oxidation

Further population-based studies may quantify incidence rates, characterize dose-dependent relationships, and investigate mechanistic pathways to optimize risk stratification and therapeutic decision-making

Hair loss (telogen effluvium) associated with GLP-1 medications is primarily caused by rapid weight loss and caloric deficit rather than the medication itself

quarterly newsletter for health professionals

It comes down to your goals, your health history, and the kind of journey you want to embark on

The rise of a new mega-sized therapy market for obesity agents could be a powerful contributory factor to the debut of the worlds first trillion-dollar value Life Sciences company, something which has not yet happened but in 2024 is moving to a real possibility